Group 1 - Zacks Premium offers various tools to help investors become more confident and informed, including daily updates on Zacks Rank and Industry Rank, Equity Research reports, and Premium stock screens [1][2] - The Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum, helping investors identify stocks with the best chances of outperforming the market in the short term [3][4] Group 2 - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors [4] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [5] - The Momentum Score identifies trends in stock prices and earnings outlooks, assisting momentum traders in timing their investments based on recent price changes [6] Group 3 - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive rating that helps investors find stocks with attractive value, strong growth potential, and positive momentum [7] - The Zacks Rank, a proprietary stock-rating model, uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] Group 4 - CVS Health Corporation is highlighted as a stock to watch, currently rated 2 (Buy) on the Zacks Rank with a VGM Score of A, indicating strong potential [12] - CVS has a Value Style Score of A, supported by a forward P/E ratio of 10.89, making it attractive to value investors [13] - Recent upward revisions in earnings estimates by 12 analysts and an increase in the Zacks Consensus Estimate to $6.11 per share further enhance CVS's investment appeal, alongside an average earnings surprise of 18.1% [13]

The Medical Services sector is experiencing significant transformation fueled by advancements in technology, increased adoption of value-based care and focus on patient-centric solutions and precision medicine. Rising demand for remote treatment is accelerating digital healthcare growth, especially in telemedicine and AI-powered analytics. Providers are using these tools to improve diagnostics, streamline operations, and enhance outcomes, while value-based models promote preventive and personalized care.Acc ...

Key Takeaways Four GARP stocks, FLEX, CVS, URBN, and EXEL, were selected using a screen focused on PEG and value scores. Each pick has a PEG ratio below industry median, solid earnings outlook and a Zacks Rank of #1 or #2. FLEX leads with a 35.1% historical growth rate, while EXEL boasts 21.2% expected long-term earnings growth.In the equity market, investments always need to be prudently hedged to overcome uncertainties and limit losses related to external shocks. A question that often arises is whether ...